Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, Hadi M. Yassine, Fatiha M. Benslimane, Hebah A. Al-Khatib, Patrick Tang, Mohammad R. Hasan, Peter Coyle, Sawsan AlMukdad, Zaina Al Kanaani, Einas Al‐Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al‐Kuwari, Adeel A. Butt, Hamad Eid Al Romaihi, Mohamed H. Al‐Thani, Abdullatif Al Khal, Roberto Bertollini
Abstract
Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.